Breast cancer vaccine HER-2/neu - GlaxoSmithKline

Drug Profile

Breast cancer vaccine HER-2/neu - GlaxoSmithKline

Alternative Names: HER-2/neu peptide vaccine - GlaxoSmithKline

Latest Information Update: 27 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 13 Sep 2004 Corixa and GlaxoSmithKline have initiated a phase I trial for Breast cancer in USA
  • 31 Dec 2003 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
  • 31 Dec 2003 Discontinued - Phase-I for Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top